Literature DB >> 30918806

Comparison of the meibomian gland dysfunction in patients with chronic ocular graft-versus-host disease and Sjögren's syndrome.

Won Choi1, Jun Young Ha1, Ying Li1, Jung Han Choi1, Yong Sok Ji1, Kyung Chul Yoon1.   

Abstract

AIM: To investigate the abnormalities in the meibomian gland in patients with dry eye disease (DED) associated with chronic ocular graft-versus-host disease (coGVHD) in comparison with Sjögren's syndrome (SS), a major form of aqueous deficient DED and meibomian gland dysfunction (MGD), a common cause of evaporative DED.
METHODS: A total 135 eyes of 135 subjects included in this study: patients with DED associated with coGVHD (n=30), patients with SS (n=35), patients with MGD (n=35), and normal controls (n=35). All participants completed the Ocular Surface Disease Index (OSDI) questionnaire, ocular surface examination [Schirmer test, tear film breakup time (TFBUT), and ocular surface staining], and meibomian gland assessment [meiboscore (gland dropout detected on meibography using infrared camera of the Keratograph 5M), meibum expressibility score (MES), meibum quality score (MQS), lid margin abnormality]. In addition, correlations of meibomian gland characteristics with ocular surface parameters as well as disease severity score were investigated in coGVHD group.
RESULTS: The coGVHD group showed significantly higher meiboscore, MES, and MQS than the other 3 groups (all P<0.05). In the coGVHD group, parameters of meibomian gland showed a significant correlation each other and those of ocular surface. The correlation between meibomian gland parameters and severity score of coGVHD was also established (meiboscore, r=0.62; MES, r=0.47; MQS, r=0.47; lid margin abnormality score, r=0.55; all P<0.05).
CONCLUSION: Patients with DED associated with coGVHD show poorer gland morphology and worse gland function than other types of DED. In addition, meibomian gland damage is not only associated with ocular surface damage but also disease severity of coGVHD.

Entities:  

Keywords:  Sjögren's syndrome; chronic ocular graft-versus-host disease; dry eye disease; meibography; meibomian gland dysfunction

Year:  2019        PMID: 30918806      PMCID: PMC6423382          DOI: 10.18240/ijo.2019.03.07

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  6 in total

Review 1.  New approaches for diagnosis of dry eye disease.

Authors:  Abdelrahman M Elhusseiny; Ali A Khalil; Reem H El Sheikh; Mohammad A Bakr; Mohamed Gaber Eissa; Yasmine M El Sayed
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

2.  Meibomian gland atrophy with duration of Sjogren's syndrome in adult females.

Authors:  Sung Rae Noh; Jae Lim Chung; Jeong Min Lee; Kyoung Yul Seo; Kyungmin Koh
Journal:  Int Ophthalmol       Date:  2021-08-19       Impact factor: 2.031

3.  Characteristics of meibomian gland dysfunction in patients with Stevens-Johnson syndrome.

Authors:  Tina Shrestha; Hyun Sik Moon; Won Choi; Hyeon Jeong Yoon; Yong Sok Ji; Mayumi Ueta; Kyung Chul Yoon
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

4.  Factors associated with ocular surface epithelial damage in patients with primary Sjögren's syndrome.

Authors:  Ji Eun Kim; Na Rae Kim; Hee Seung Chin; Kyoung Yul Seo; Tae-Im Kim; Ji Won Jung
Journal:  BMC Ophthalmol       Date:  2021-03-02       Impact factor: 2.209

Review 5.  Update on ocular graft-versus-host disease.

Authors:  Sridevi Nair; Murugesan Vanathi; Ritika Mukhija; Radhika Tandon; Sandeep Jain; Yoko Ogawa
Journal:  Indian J Ophthalmol       Date:  2021-05       Impact factor: 1.848

6.  Massive Demodicosis of the Eyes in a Patient with Sjögren Syndrome: A Case Report.

Authors:  Marta Ziaja-Sołtys; Magdalena Kołodziejczyk; Beata Rymgayłło-Jankowska; Dominika Wróbel-Dudzińska; Ewa Suchodoła-Ratajewicz; Dominika Szlonzak; Tomasz Żarnowski; Anna Bogucka-Kocka
Journal:  Acta Parasitol       Date:  2020-10-31       Impact factor: 1.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.